ଓମେଗା-3 ଏସିଡ ଇଥାଇଲ ଇଷ୍ଟର ସମୂହ

ଓମେଗା-3 ଏସିଡ ଇଥାଇଲ ଇଷ୍ଟର ସମୂହ
	Chemical structure of ethyl eicosapentaenoate, an important omega-3 acid ethyl ester
Combination of
Eicosapentaenoic acid	Antilipemic agent
Docosahexaenoic acid	Antilipemic agent
Clinical data
Trade names	Lovaza, Omtryg, others
AHFS/Drugs.com	monograph
data	EU EMA: yes; US DailyMed: Omega-3-acid_ethyl_esters;
Pregnancy; category	AU: B1 ; US: C (Risk not ruled out) ; ;
Routes of; administration	By mouth
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);

ଓମେଗା-3 ଏସିଡ ଇଥାଇଲ ଇଷ୍ଟର ସମୂହ (ଇଂରାଜୀ ଭାଷାରେ Omega-3 acid ethyl esters ) ହେଉଛି ଓମେଗା-3 ଫ୍ୟାଟି ଏସିଡ୍ ଇକୋସାପେଣ୍ଟେନୋଇକ ଏସିଡ (ଇପିଏ) ଏବଂ ମାଛ ତେଲରେ ମିଳୁଥିବା ଡୋକୋସାହେକ୍ସେନୋଇକ ଏସିଡ (DHA) ମିଶ୍ରଣ ।^[୩] ଖାଦ୍ୟପେୟର ପରିବର୍ତ୍ତନ ସହିତ, ସେଗୁଡ଼ିକ ଉଚ୍ଚ ରକ୍ତ ଟ୍ରାଇଗ୍ଲିସେରାଇଡ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯାହାଦ୍ୱାରା ଅଗ୍ନାଶୟ ପ୍ରଦାହ ରୋଗର ଆଶଙ୍କା ହ୍ରାସ ହୋଇପାରେ ।^[୩]^[୪] ସେଗୁଡିକ ସାଧାରଣତଃ ଷ୍ଟାଟିନ୍ ଅପେକ୍ଷା କମ୍ ପସନ୍ଦ କରାଯାଏ ଏବଂ ଏନଏଚଏସ ସ୍କଟଲ୍ୟାଣ୍ଡଦ୍ୱାରା ବ୍ୟବହାର କରିବାକୁ ସୁପାରିଶ କରାଯାଏ ନାହିଁ କାରଣ ହୃଦଘାତର ଆଶଙ୍କା ହ୍ରାସ କରିବା ସମର୍ଥନ କରେନାହିଁ । ^[୩] ^[୫] ^[୬] ଓମେଗା-୩ ଏସିଡ ଇଥାଇଲ ଇଷ୍ଟର ପାଟିରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଢକାର, ବାନ୍ତି, ଏବଂ ପେଟ ବ୍ୟଥା ହୋଇପାରେ । ^[୩] ^[୫] ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା ଏବଂ ଆନାଫାଇଲକ୍‌ସିସ ହୋଇପାରେ ।^[୩] ଗର୍ଭାବସ୍ଥାରେ ଏହାର ବ୍ୟବହାର ଭଲ ଭାବରେ ଅଧ୍ୟୟନ କରାଯାଇ ନ ଥିବାବେଳେ କେତେକ ଓମେଗା-୩ ଫ୍ୟାଟି ଏସିଡ ଉପକାରୀ ହେବା ଦେଖାଯାଏ ।^[୧] ଏହା କିପରି କାମ କରେ ତାହା ସଂପୂର୍ଣ୍ଣ ସ୍ପଷ୍ଟ ନୁହେଁ ।^[୩]

୨୦୦୦ ମସିହାରେ ୟୁରୋପୀୟ ୟୁନିଅନରେ ଏବଂ ୨୦୦୪ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ପାଇଁ ଓମେଗା-୩ ଏସିଡ ଇଥାଇଲ ଇଷ୍ଟର ଔଷଧ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୬] ^[୭] ^[୩] ଏହା ଏକ ବଂଶଗତ ବା ଜେନେରିକ ଔଷଧ ଏବଂ କାଉଣ୍ଟର ଉପରେ ଉପଲବ୍ଧ ।^[୫] ^[୩] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୧୯ ସୁଦ୍ଧା ଏକ ମାସ ଔଷଧ ଯୋଗାଣ ମୂଲ୍ୟ ୬ ପାଉଣ୍ଡ ଥିଲା ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୭.୫୦ ଡଲାର ଅଟେ ।^[୮] ୨୦୧୭ରେ, ଏହା ଆମେରିକାର ୧୫୮ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ତିନି ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ ରହିଥିଲା ।^[୯] ^[୧୦]

ଆଧାର ସମ୍ପାଦନା

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Omega-3 polyunsaturated fatty acids Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 April 2019. Retrieved 13 April 2019.
↑ "Summary of Product Characteristics (SmPC) - (emc)". Omacor. 11 December 2019. Archived from the original on 13 August 2019. Retrieved 15 May 2020.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ ^୩.୭ ^୩.୮ "Omega-3-acid Ethyl Esters Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 13 April 2019. Retrieved 13 April 2019.
↑ Karalis DG (February 2017). "A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids". Advances in Therapy. 34 (2): 300–323. doi:10.1007/s12325-016-0462-y. PMC 5331085. PMID 27981496.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 206–207. ISBN 9780857113382.
↑ ^୬.୦ ^୬.୧ "Omega-3 fatty acid medicines". European Medicines Agency. 17 September 2018. Archived from the original on 13 April 2019. Retrieved 13 April 2019.
↑ "Drug Approval Package: Omacor (Omega-3-Acid Ethyl Esters) NDA #021654". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 2 February 2020. Retrieved 15 May 2020.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
↑ "Omega-3-acid Ethyl Esters - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.

[Preg2019-1] ୧.୦ ^୧.୧ ^୧.୨ "Omega-3 polyunsaturated fatty acids Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 April 2019. Retrieved 13 April 2019.

[emc-2] "Summary of Product Characteristics (SmPC) - (emc)". Omacor. 11 December 2019. Archived from the original on 13 August 2019. Retrieved 15 May 2020.

[AHFS2019-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ ^୩.୭ ^୩.୮ "Omega-3-acid Ethyl Esters Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 13 April 2019. Retrieved 13 April 2019.

[4] Karalis DG (February 2017). "A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids". Advances in Therapy. 34 (2): 300–323. doi:10.1007/s12325-016-0462-y. PMC 5331085. PMID 27981496.

[BNF76-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 206–207. ISBN 9780857113382.

[EMA2019-6] ୬.୦ ^୬.୧ "Omega-3 fatty acid medicines". European Medicines Agency. 17 September 2018. Archived from the original on 13 April 2019. Retrieved 13 April 2019.

[FDA_approval-7] "Drug Approval Package: Omacor (Omega-3-Acid Ethyl Esters) NDA #021654". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 2 February 2020. Retrieved 15 May 2020.

[NADAC2019-8] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-9] "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.

[ref1-10] "Omega-3-acid Ethyl Esters - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.

[୩]

[୪]

[୫]

[୬]

[୧]

[୨]

[୭]

[୮]

[୯]

[୧୦]